Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin c Mega-Dose tested against deadly sepsis

NCT ID NCT05194189

Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving very high doses of vitamin C to people with sepsis (a severe infection that can cause organ failure) could reduce the risk of death within 28 days. 234 adults in the ICU received either vitamin C or a placebo for up to 4 days. The main goal was to see if vitamin C lowered death rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

234 people

The number who actually took part.

Started

Feb 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets the diagnostic criteria for sepsis-3 developed by the American Society of Critical Care Medicine (SCCM)/European Critical Care Medicine Association (ESICM) * Age ≥18 years old and age ≤80 years old. * Procalcitonin ≥2 ng/ml Exclusion Criteria: * Age\<18 years, or age\>80 years. * Pregnancy or lactating * A solid-organ or bone marrow transplant patients. * Patients with myocardial infarction within the past 3 months. * Advanced pulmonary fibrosis . * Patients with cardiopulmonary resuscitation before enrollment. * HIV-positive patients. * granulocyte-deficient patients. * blood/lymphatic system tumors are not remission. * patients with limited care (lack of commitment to full aggressive life support). * patients with long-term use of immunosuppressive drugs or with immunodeficiency. * patients with advanced tumors. * patients combined with non-infectious factors leading to the death(uncontrollable major bleeding, brain hernia, etc.). * surgically unresolved infection sources(such as some intraperitoneal infection etc.) * patients allergic to vitamin c. * patients with G6PD deficiency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis Septic shock

Contacts and locations

Locations

  • Department of Critical Care Medicine of Nanfang Hospital of Southern Medical University

    Guanzhou, China

  • Department of Critical Care Medicine of Yunfu People's Hospital

    Yunfu, Guangdong, 527300, China

  • Department of Critical Care Medicine of Zhongshan People's Hospital

    Zhongshan, Guangzhou, 528403, China

  • Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University

    Guanzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.